Roche is buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion after developments in this area convinced the Swiss drugmaker to “step up”, Chief Executive Severin Schwan said.

Teva Pharmaceutical Industries said its 2018 results would be weaker than expected and that the company might encounter delays for an important new migraine drug, pushing the drugmaker’s shares down more than 9 percent.

Scientists have for the first time fixed a protein defect that causes Huntington’s disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease.

Teva Pharmaceutical Industries Ltd. announced that the U.S. FDA approved Austedo (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults.

Teva finally won approval from the U.S. FDA for Austedo, a treatment for chorea associated with Huntington’s disease.

Raptor Pharmaceutical Corp said it plans to advance development of its brain disorder drug to a registration study, despite it failing to show statistical significance in a trial. The drug, RP103, is being evaluated in patients with Huntington’s Disease, a type of neurodegenerative genetic disorder that affects muscle coordination and leads to mental decline and […]

Raptor Pharmaceutical Corp lost more than a third of its market value after the company said it did not plan to develop its liver drug, which failed to meet the main goal in a second mid-stage study. The company’s shares plunged 35.5 percent to $7.61 in premarket trading on Monday. The study was testing the […]